Monograph

B02BD03 - Factor VIII Inhibitor Bypassing Activity

Not porphyrinogenic

Rationale

Enzymes. No CYP-interactions.

Chemical description

Coagulation factor concentrate (IX, II, X) administered as infusion in bleeding hemophilia A patients with faxtor VIII antibodies.

Similar drugs

Explore alternative drugs in similar therapeutic classes B02B / B02BD or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

FEIBA · FEIBA 100 E/ml, poeder en oplosmiddel voor oplossing voor infusie · FEIBA 25 E/ml, poeder en oplosmidel voor oplossing voor infusie · FEIBA 50 E/ml, poeder en oplosmidel voor oplossing voor infusie

Belgium

Feiba U · Feiba 1 000 U sol. inj. (pdr. + solv.) i.v. flac. · Feiba 500 U sol. inj. (pdr. + solv.) i.v. flac.

United Kingdom

FEIBA · FEIBA 25units/ml (500unit) powder and 20ml solvent for solution for infusion vials · FEIBA 50units/ml (1,000unit) powder and 20ml solvent for solution for infusion vials · FEIBA 50units/ml (2,500unit) powder and 50ml solvent for solution for infusion vials · FEIBA 50units/ml (500unit) powder and 10ml solvent for solution for infusion vials

Denmark